Finding
Sackler Family and Purdue Pharma Agree to Enhanced $7.4 Billion Opioid Settlement
Sackler family, Purdue Pharma, opioid settlement, $7.4 billion, multistate agreement, opioid crisis, addiction treatment, recovery programs
Novo Nordisk’s Obesity Drug Breakthrough: 22% Weight Loss at Week 36 Boosts Stock by 11%
Novo Nordisk, Obesity drug, 22% weight loss, Stock surge, Next-gen obesity treatment, Amycretin, Semaglutide, Pharmaceutical industry
Breaking the Silence: Endo’s “I Got Somebody” Campaign Encourages Men to Seek Help for Peyronie’s Disease
Peyronie’s disease, men’s health, Endo, “I Got Somebody” campaign, urology specialists, nonsurgical treatment options, disease awareness, stigma reduction.
Tris Pharma Achieves Significant Milestone with Non-Opioid Painkiller Cebranopadol in Phase III Trials
Non-opioid pain medication, Cebranopadol, Tris Pharma, Phase III trials, Pain management, Reduced abuse potential, Dual-NMR agonist
Revitalizing Maternal Health: Nonprofit Leverages Low-Dose Aspirin to Combat Preeclampsia Disparities
Preeclampsia, Maternal Health Equity, Low-Dose Aspirin, GAP—SPIRIN, Health Disparities, Black Maternal Health
Trump’s Second Term: Mifepristone Battle Looms as Early Test of Abortion Stance
Mifepristone, abortion, Trump, second term, reproductive rights, FDA, Supreme Court
Novartis Secures Temporary Block on Generic Version of Entresto
Novartis, Entresto, generic version, MSN Pharmaceuticals, temporary block, heart failure drug
Hengrui and Kailera’s Obesity Drug HRS9531 Shows Promising Results in Phase 2 Trial
HRS9531, Obesity treatment, GLP-1/GIP receptor dual agonist, Phase 2 clinical trial, Weight loss, Hengrui Pharmaceuticals, Kailera Therapeutics
Leyden Labs Secures $70 Million Funding to Develop Broad Protection Against Respiratory Viruses
Leyden Labs, Respiratory viruses, Influenza, Nasal defenses, Broad protection, PanFlu, Mucosal Protection Platform, Biotech funding
LB-102: Promising Phase 2 Results Revive Benzamide Antipsychotics for Schizophrenia Treatment in the US
LB-102, schizophrenia, benzamide antipsychotics, Phase 2 trial, PANSS scores, safety profile, once-daily dosing